Fundraising FoxAytu Bioscience
Englewood, US · Delaware corporation · 1 known investors
Find your way into Aytu Bioscience
Sign up to see every warm intro you have to Aytu Bioscience
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aytu Bioscience team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Biopharmaceutical company that went public on NASDAQ in 2021 (AADI)
Founders & leadership
JT
Jarrett T. DisbrowExecutive
JR
Joshua R. DisbrowExecutive
GA
Gregory A. GouldExecutive
Board
MM
Michael MacalusoBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$28.8M disclosed across 4 rounds · 2015–2019
▶$10MraisedOct 2019 · 2 investors · PharmaceuticalsRule 506(b)
▶$10MraisedOct 2019 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gary CantrellDirector
- Steven BoydDirector
- Carl DockeryDirector
- Josh DisbrowDirector, Executive Officer
- Jarrett DisbrowExecutive Officer
- Ketan MehtaDirector
- Michael MacalusoDirector
- John Donofrio Jr.Director
- David GreenExecutive Officer
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $800K
- Placement agents
- Ladenburg Thalmann & Co. Inc.
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.8MraisedAug 2017 · 70 investors · PharmaceuticalsRule 506(b)
▶$11.8MraisedAug 2017 · 70 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael MacalusoDirector
- Gary V. CantrellDirector
- Gregory A. GouldExecutive Officer
- John A. Donofrio, Jr.Director
- Jarrett T. DisbrowExecutive Officer
- Joshua R. DisbrowExecutive Officer, Director
- Carl C. DockeryDirector
- Offering amount
- $11.8M
- Amount sold
- $11.8M
- Sales commissions
- $1.1M
- Placement agents
- Joseph Gunnar & Co., LLC, Fordham Financial Management, Inc.
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.8MraisedMay 2017 · 16 investors · PharmaceuticalsRule 506(b)
▶$1.8MraisedMay 2017 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael MacalusoDirector
- Joshua R. DisbrowExecutive Officer, Director
- Jarrett T. DisbrowExecutive Officer
- Gregory A. GouldExecutive Officer
- Carl C. DockeryDirector
- Gary V. CantrellDirector
- John A. Donofrio, Jr.Director
- Amount sold
- $1.8M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$5.2MraisedSep 2015 · 96 investors · PharmaceuticalsRule 506(b)
▶$5.2MraisedSep 2015 · 96 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jarrett T. DisbrowExecutive Officer
- Michael MacalusoDirector
- Joshua R. DisbrowExecutive Officer
- Gregory A. GouldExecutive Officer
- Offering amount
- $6M
- Amount sold
- $5.2M
- Sales commissions
- $244K
- Placement agents
- Newbridge Securities Corporation
- First sale
- Aug 2015
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Aytu Bioscience do?
- Biopharmaceutical company that went public on NASDAQ in 2021 (AADI)
- Who are Aytu Bioscience's investors?
- Aytu Bioscience's investors include Decheng Capital.
- How much funding has Aytu Bioscience raised?
- Aytu Bioscience has disclosed $28.8M raised across 4 rounds.
- Where is Aytu Bioscience headquartered?
- Aytu Bioscience is headquartered in Englewood, US.